218 related articles for article (PubMed ID: 32640933)
21. The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor.
Lawendy N; Lamba M; Chan G; Wang R; Alvey CW; Krishnaswami S
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):421-7. PubMed ID: 27129117
[TBL] [Abstract][Full Text] [Related]
22. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y
Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444
[TBL] [Abstract][Full Text] [Related]
23. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.
Pantavou K; Yiallourou AI; Piovani D; Evripidou D; Danese S; Peyrin-Biroulet L; Bonovas S; Nikolopoulos GK
United European Gastroenterol J; 2019 Dec; 7(10):1285-1303. PubMed ID: 31839954
[TBL] [Abstract][Full Text] [Related]
25. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.
D'Amico F; Fiorino G; Furfaro F; Allocca M; Danese S
Expert Opin Investig Drugs; 2018 Jul; 27(7):595-599. PubMed ID: 29938545
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study.
Shin JW; Huh CH; Kim MW; Lee JS; Kwon O; Cho S; Park HS
Acta Derm Venereol; 2019 Jan; 99(1):41-46. PubMed ID: 30281139
[TBL] [Abstract][Full Text] [Related]
27. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.
Sandborn WJ; Panés J; D'Haens GR; Sands BE; Su C; Moscariello M; Jones T; Pedersen R; Friedman GS; Lawendy N; Chan G
Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1541-1550. PubMed ID: 30476584
[TBL] [Abstract][Full Text] [Related]
28. Tofacitinib for the treatment of lichen planopilaris: A case series.
Yang CC; Khanna T; Sallee B; Christiano AM; Bordone LA
Dermatol Ther; 2018 Nov; 31(6):e12656. PubMed ID: 30264512
[TBL] [Abstract][Full Text] [Related]
29. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
Chaparro M; Garre A; Mesonero F; Rodríguez C; Barreiro-de Acosta M; Martínez-Cadilla J; Arroyo MT; Manceñido N; Sierra-Ausín M; Vera-Mendoza I; Casanova MJ; Nos P; González-Muñoza C; Martínez T; Boscá-Watts M; Calafat M; Busquets D; Girona E; Llaó J; Martín-Arranz MD; Piqueras M; Ramos L; Surís G; Bermejo F; Carbajo AY; Casas-Deza D; Fernández-Clotet A; García MJ; Ginard D; Gutiérrez-Casbas A; Hernández L; Lucendo AJ; Márquez L; Merino-Ochoa O; Rancel FJ; Taxonera C; López Sanromán A; Rubio S; Domènech E; Gisbert JP
J Crohns Colitis; 2021 Jan; 15(1):35-42. PubMed ID: 32969471
[TBL] [Abstract][Full Text] [Related]
30. Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.
Castañeda OM; Romero FJ; Salinas A; Citera G; Mysler E; Rillo O; Radominski SC; Cardiel MH; Jaller JJ; Alvarez-Moreno C; Ponce de Leon D; Castelli G; García EG; Kwok K; Rojo R
J Clin Rheumatol; 2017 Jun; 23(4):193-199. PubMed ID: 28145906
[TBL] [Abstract][Full Text] [Related]
31. Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study.
Panés J; D'Haens GR; Higgins PDR; Mele L; Moscariello M; Chan G; Wang W; Niezychowski W; Su C; Maller E
Aliment Pharmacol Ther; 2019 Feb; 49(3):265-276. PubMed ID: 30663107
[TBL] [Abstract][Full Text] [Related]
32. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
[TBL] [Abstract][Full Text] [Related]
33. Is tofacitinib a game-changing drug for ulcerative colitis?
Magro F; Estevinho MM
United European Gastroenterol J; 2020 Aug; 8(7):755-763. PubMed ID: 32552501
[TBL] [Abstract][Full Text] [Related]
34. Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
Sands BE; Sandborn WJ; Feagan BG; Lichtenstein GR; Zhang H; Strauss R; Szapary P; Johanns J; Panes J; Vermeire S; O'Brien CD; Yang Z; Bertelsen K; Marano C;
J Crohns Colitis; 2018 Nov; 12(10):1158-1169. PubMed ID: 29917064
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of JAK inhibitors in Crohn's Disease.
Rogler G
J Crohns Colitis; 2020 Aug; 14(Supplement_2):S746-S754. PubMed ID: 31781755
[TBL] [Abstract][Full Text] [Related]
36. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
Sandborn WJ; Ghosh S; Panes J; Vranic I; Su C; Rousell S; Niezychowski W;
N Engl J Med; 2012 Aug; 367(7):616-24. PubMed ID: 22894574
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis.
Bagherani N; Smoller BR
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28133877
[No Abstract] [Full Text] [Related]
38. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Kuo CM; Tung TH; Wang SH; Chi CC
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):355-362. PubMed ID: 29136293
[TBL] [Abstract][Full Text] [Related]
39. Single- and multiple-dose pharmacokinetics of tofacitinib in healthy Chinese volunteers.
Krishnaswami S; Wang T; Yuan Y; Alvey CW; Checchio T; Peterson M; Shi H; Riese R
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):395-9. PubMed ID: 27137149
[TBL] [Abstract][Full Text] [Related]
40. Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention.
Colombel JF
Inflamm Bowel Dis; 2018 Sep; 24(10):2173-2182. PubMed ID: 29788127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
